JPMorgan Nasdaq Equity Premium Income ETF vs uniQure N.V. Ordinary Shares — how do they compare? JPMorgan Nasdaq Equity Premium Income ETF trades at $59.72 (market cap $44.60B), while uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B). The key difference: JPMorgan Nasdaq Equity Premium Income ETF is far larger — about 30.1× uniQure N.V. Ordinary Shares's market cap, and JPMorgan Nasdaq Equity Premium Income ETF is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Nasdaq Equity Premium Income ETF for 67 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| JEPQ | QURE | |
|---|---|---|
Market Cap | $44.60B | $1.48B |
Volume | 3,957,816 | 2,488,780 |
Sector | Income / Options Overlay | Health |
52-Week High | $61.46 | $70.59 |
52-Week Low | $53.77 | $9.03 |
Typical Hold Time | 67 Days | 0 Days |
Enterprise Value | — | $728.62M |
Signals from Pluang's Aura AI — not financial advice
JEPQ trades at $60.92, showing minimal daily movement with a neutral technical signal. The ETF maintains a covered-call strategy focused on Nasdaq exposure, generating monthly income through dividends. Recent distributions have shown variability, with payouts ranging from $0.57 to $0.70 per share. Moving averages indicate bullish momentum while oscillators remain neutral, suggesting balanced near-term positioning.
The ETF offers high-yield income potential with an estimated 11% annualized yield, though price appreciation may be limited by the covered-call strategy. Key risks include market volatility dependence and potential tax implications from return of capital. Institutional interest remains strong, with recent acquisitions signaling confidence in the income strategy.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
JEPQ seeks to provide monthly income and exposure to the Nasdaq-100 Index with less volatility. It uses a methodology that combines high-growth tech stocks with an options strategy to capture income.
Read more on JEPQ →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →